Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
InhaleRx Limited ( (AU:IRX) ) just unveiled an announcement.
InhaleRx Limited has announced the dispatch of its Entitlement Offer Prospectus, opening the offer for subscription to eligible shareholders. The offer is part of the company’s strategy to fund the development of its inhaled therapies, with significant economic opportunities anticipated for shareholders. The timeline for the offer includes a closing date on December 17, 2025, and subsequent announcements and meetings scheduled into January 2026.
More about InhaleRx Limited
InhaleRx Limited is an Australian clinical stage drug development company focused on creating rapid onset, inhaled therapies for unmet medical needs in pain management and mental health sectors. The company is working on treatments for Breakthrough Cancer Pain, Panic Disorder, and Treatment-Resistant Depression, aiming for U.S. FDA approval through efficient regulatory pathways.
Average Trading Volume: 260,333
Technical Sentiment Signal: Sell
Current Market Cap: A$6.15M
See more data about IRX stock on TipRanks’ Stock Analysis page.